Horizon Pharma

Horizon CEO Tim Walbert knows patients because he is one
Horizon CEO Tim Walbert knows patients because he is one
Medical Marketing and Media
Tim Walbert
Horizon Pharma
Pharma CEOs
autoimmune disease
Duexis
patients
Flag link:
Horizon dives into eye treatments with River Visions acquisition
Horizon dives into eye treatments with River Visions acquisition
BioPharma Dive
Horizon Pharma
River Visions
M&A
eye health
Flag link:
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Horizon Pharma buys River Vision and its fast-tracked eye med for $145M
Fierce Biotech
Horizon Pharma
River Vision
eye health
teprotumumab
thyroid eye disease
Flag link:
Tapping into the rare disease market
Tapping into the rare disease market
BioPharma Dive
Rare Diseases
Incyte
Horizon Pharma
Lundbeck
Flag link:
Horizon Pharma - Aggressive Acquirer Makes Another Move
Horizon Pharma - Aggressive Acquirer Makes Another Move
Seeking Alpha
Horizon Pharma
M&A
Flag link:
Horizon Buys Rare-Disease Company Raptor for $800 Million
Horizon Buys Rare-Disease Company Raptor for $800 Million
Bloomberg
Horizon Pharma
M&A
Rare Diseases
Raptor Pharmaceutical
Procybi
Quinsair
Flag link:
With new additions, PhRMA opens door to generics drugmaker Teva
With new additions, PhRMA opens door to generics drugmaker Teva
BioPharma Dive
PhRMA
generics
Teva Pharmaceuticals
Alexion
Amag Pharmaceuticals
Horizon Pharma
Jazz Pharmaceuticals
Flag link:
Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade
Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade
Investors.com
Horizon Pharma
earnings
Depomed
Flag link:
Horizon expects most sales to come later in the year, precipitating share's slide
Horizon expects most sales to come later in the year, precipitating share's slide
BioPharma Dive
Horizon Pharma
Flag link:
Horizon Pharma Raises CEO Walbert's Pay 10-Fold to $93.4 Million
Horizon Pharma Raises CEO Walbert's Pay 10-Fold to $93.4 Million
Bloomberg
Horizon Pharma
executive pay
Timothy Walbert
Flag link:
Aiming for $250M in sales, Horizon quadruples force behind gout med Krystexxa
Aiming for $250M in sales, Horizon quadruples force behind gout med Krystexxa
Fierce Pharma Marketing
drug reps
Horizon Pharma
Krystexxa
gout
Flag link:
Depomed isn't anti-takeover, CEO says. It was just anti-Horizon
Depomed isn't anti-takeover, CEO says. It was just anti-Horizon
Fierce Pharma
Depomed
Horizon Pharma
M&A
Jim Schoeneck
Flag link:
Horizon drops hostile bid for Depomed after judge's ruling
Horizon drops hostile bid for Depomed after judge's ruling
Yahoo/AP
Horizon Pharma
Depomed
M&A
Flag link:
$2 billion offer extended by hostile bidder of Depomed
$2 billion offer extended by hostile bidder of Depomed
Bizjournals.com
Depomed
Horizon Pharma
M&A
Flag link:
Horizon swipes back at Express Scripts as PBM cuts off drugmaker's specialty pharma
Horizon swipes back at Express Scripts as PBM cuts off drugmaker's specialty pharma
BioPharma Dive
Horizon Pharma
Express Scripts
PBMs
Linden Care
Flag link:
Express Scripts cuts off pharmacy that sells drugs for Horizon Pharma
Express Scripts cuts off pharmacy that sells drugs for Horizon Pharma
Pharmalot
Express Scripts
Horizon Pharma
Flag link:
One Reason We Think Biotech Has Bottomed
One Reason We Think Biotech Has Bottomed
Seeking Alpha
biotech
Allergan
AstraZeneca
Bristol-Myers Squibb
Celgene
Gilead Sciences
Horizon Pharma
Insys
Pfizer
Retrophin
Valeant Pharmaceuticals
ZS Pharma
Flag link:
Horizon Pharma Shows It's Not Valeant
Horizon Pharma Shows It's Not Valeant
Seeking Alpha
Horizon Pharma
Valeant Pharmaceuticals
Flag link:
Drugmakers Are Distancing Themselves From Valeant
Drugmakers Are Distancing Themselves From Valeant
Bloomberg
Valeant Pharmaceuticals
Endo International
Allergan
Horizon Pharma
Mallinckrodt
Flag link:
Horizon Pharma passes regulatory waiting period in its hostile pursuit of Depomed
Horizon Pharma passes regulatory waiting period in its hostile pursuit of Depomed
Yahoo/AP
Horizon Pharma
Depomed
M&A
Flag link: